Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.
VEEV's strong Q2 results, expanding Vault CRM adoption and diversified product portfolio support growth prospects, though market saturation poses risks.
Veeva Systems is Monday's IBD Stock Of The Day. Veeva stock is butting up against a ceiling at its 21-day moving average.
2026-11-05. The following slide deck was published by Veeva Systems Inc.
Veeva earns a Buy rating, justified by re-accelerating revenue growth, rare 45% operating margins, and sticky regulated software. Read more on VEEV stock here.
Veeva Systems earns a buy, as core business growth re-accelerates, with AI-driven upside from Falcon agents not yet priced in. Read more on VEEV stock here.
See why Veeva Systems stock is rebounding as revenue growth, CRM retention, free cash flow, and buybacks boost confidence.
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Veeva Systems' (VEEV) guidance implied a potential further deceleration for the company's research a
Zacks.com users have recently been watching Veeva (VEEV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Veeva Systems stock moves above a buy point in its chart pattern. The medical software maker's stock is popular among mutual funds.
Veeva Systems (NYSE:VEEV) has outperformed the market over the past 10 years by 9.08% on an annualized basis producing an average annual return of 22.87%. Currently, Veeva Systems has a market capitalization of $47.90
Veeva Systems (VEEV) reached $301.63 at the closing of the latest trading day, reflecting a +1.95% change compared to its last close.
Detailed price information for Veeva Systems Inc (VEEV-N) from The Globe and Mail including charting and trades.
Veeva Systems briefly broke out of a flat base.
This is the newest page. Registered accounts read further back.